Dave joined the company as a research chemist in 1981 after completing his MA and BA at Oriel College, Oxford.  During his career he has also worked on discovering antibiotics and cardiovascular medicines, as both a medicinal chemist and project leader.

  Dave Allen is the head of the Respiratory Therapy Area at GSK and is responsible for the identification of novel differentiated medicines and their progression to registration and launch.  He leads a group of over 200 scientists and clinicians who exploit scientific innovations that have the potential to address the major unmet needs in diseases such as COPD, severe asthma, acute lung injury and idiopathic pulmonary fibrosis.